Fundz

Inflammatix Announces Additional $12.1 Million Funding From Barda For Virabac Ez Acute Infection Test

PRIVATENov 18, 2021

Amount Raised

$12.1 Million

Round Type

Funding Round

SunnyvaleBiotechnology

Description

Inflammatix, a pioneering molecular diagnostics company, announced today a contract extension of $12.1 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. The funding is part of a BARDA contract worth up to $72 million if all options are exercised.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Inflammatix that raised within 45 days of this round, from Fundz verified event records.

  • Immunoprofile raised $880K on December 31, 2021.
  • Venus Concept Inc. raised $12M on December 30, 2021.
  • Apic Bio, Inc. raised $4M (Seed) on December 30, 2021.
  • Arbutus raised $15M on December 30, 2021.
  • Trait Biosciences Inc. raised an undisclosed amount (Series A) on December 30, 2021.
  • ViTToria Biotherapeutics, Inc. raised $8.7M on December 30, 2021.

Who to call at Inflammatix, and when

A new round usually means Inflammatix is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Inflammatix raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Inflammatix, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Inflammatix. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Inflammatix

Location

540 Oakmead Pkwy

Sunnyvale, California, United States

About

Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Inflammatix raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsTim S., Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Inflammatix's next move

See what Strategic adds

Inflammatix raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.